Effectiveness of the Telemonitoring Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Starting soon · Not applicable

Conditions studied: BPCO

In brief

Telemonitoring systems have already demonstrated their ability to improve clinical follow-up and reduce healthcare resource utilization in patients with chronic respiratory failure treated with non-invasive ventilation (NIV) and/or long-term oxygen therapy (LTOT). In this severely ill population, telemonitoring enables earlier detection of clinical deteriorations, optimization of therapeutic interventions, and a reduction in unplanned hospitalizations. Building on these findings, we hypothesize that similar benefits could be achieved in patients with chronic obstructive pulmonary disease (COPD) who are at risk of exacerbations, regardless of their clinical severity (GOLD ABE classification). The implementation of a structured telemonitoring program in this population could therefore help reduce the severity of exacerbations and, ultimately, decrease overall healthcare resource utilization.

Key facts

Study ID

NCT07697105

Run by

Hope Care, S.A

People needed

340

Starts

2026-08-01

Expected to finish

2028-11-30

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female aged 18 years or older.
• Patient with a confirmed diagnosis of chronic obstructive pulmonary disease (COPD), classified according to the GOLD ABE classification, who has experienced at least one COPD exacerbation within the previous 12 months.
• Able and willing to provide written informed consent.
• Able to comply with the telemonitoring procedures, including:
• Performing physiological measurements on a regular basis;
• Completing the required questionnaires.
• Covered by a valid health insurance or social security scheme.

You may not qualify if…

• Receiving long-term oxygen therapy (LTOT) or non-invasive ventilation (NIV), regardless of the duration since prescription.
• Presence of severe, unstable comorbidities that may interfere with the study outcomes, including but not limited to:
• Decompensated heart failure;
• Chronic kidney disease;
• Asthma;
• Other restrictive pulmonary diseases;
• Psychotic mental disorders.
• Participation in another interventional clinical study within the month preceding enrollment or during the study period.
• Unavailable for follow-up or planning to relocate before completion of study participation.
• Protected populations, including:
• Pregnant or breastfeeding women, or women planning to become pregnant during the study period. For women of childbearing potential not using effective contraception, pregnancy will be ruled out by a urine or blood human chorionic gonadotropin (hCG) test before enrollment.
• Individuals deprived of liberty by judicial or administrative decision, or individuals under legal protection measures.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.